https://www.taxtmi.com/caselaws?id=63291 The Tribunal upheld the CIT(A)'s decision, ruling that the expenditure of Rs. 47,71,110 incurred by the pharmaceutical company for marketing purposes was of a revenue nature and fully deductible. The Tribunal dismissed the Revenue's appeal, emphasizing that the classification of the expenditure as 'deferred revenue expenditure' in the books did not affect its deductibility and that the enduring benefit test was not conclusive. The Tribunal aligned with the CIT(A) in determining that the expenses facilitated trading operations without impacting fixed capital, thus confirming the assessee's claim for full deduction. en-us Mon, 08 Nov 2004 00:00:00 +0530 Sat, 25 May 2024 12:07:00 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=63291 The Tribunal upheld the CIT(A)'s decision, ruling that the expenditure of Rs. 47,71,110 incurred by the pharmaceutical company for marketing purposes was of a revenue nature and fully deductible. The Tribunal dismissed the Revenue's appeal, emphasizing that the classification of the expenditure as 'deferred revenue expenditure' in the books did not affect its deductibility and that the enduring benefit test was not conclusive. The Tribunal aligned with the CIT(A) in determining that the expenses facilitated trading operations without impacting fixed capital, thus confirming the assessee's claim for full deduction. Case-Laws Income Tax Mon, 08 Nov 2004 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=63291